Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. ...Read More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
A recent study performed in Japan compared the safety and efficacy of a Brainsway deep TMS H-coil, a standard figure-8 TMS coil and a sham coil (placebo) for the treatment of 18 patients suffering from neuropathic pain. All patients received all three types of treatment in a crossover design. It was found that only the deep TMS H-coil induced significant pain improvements, while the results of the figure-8 were not significantly different than the sham. The treatment was well tolerated and no serious adverse events were reported.